|
Market Cap (19-May) $17,684,784 (923rd) |
Close (30-Jun) $0.125 |
Volume (30-Jun) 0 |
Shortsold (17-Apr) 8,415 (0.00%) (600th) |
|
52w High $0.064 |
52w Low $0.021 |
P/E - |
EPS 0 |
EMD released this announcement to the ASX on 18 March 2022, 18:16. The announcement is not marked as price sensitive, and is 12 page(s) in length and 808.77kb in size.
You can view all announcements from EMD and see how they appear on a price chart on the announcements page.
At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 600th as of the latest reported data (17 April 2025).
| Other Recent Announcements from EMD | |
|---|---|
| Trading Halt | 29 June 2023, 9:33 |
| Emyria Receives Ethics Approval for MDMA-assisted Therapy | 8 June 2023, 9:10 |
| Section 708A(5)(e) Notice | 10 May 2023, 18:37 |
| Addendum to Notice of Meeting and Proxy Form | 18 March 2022, 18:16 |
| Emyria launches second ultra-pure CBD capsule | 17 March 2022, 10:32 |
| EMD-RX5 program advancing Phase 1 clinical trials underway | 17 March 2022, 9:58 |
| Recruitment commenced for EMD-RX5 Phase 1 Study | 9 March 2022, 9:47 |
You must be logged in to post a reply.
Emyria 